<DOC>
	<DOCNO>NCT00004169</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness chemotherapy , radiation therapy , peripheral stem cell transplantation treat patient recurrent refractory Hodgkin 's disease .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Peripheral Stem Cell Transplantation Treating Patients With Hodgkin 's Disease</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity response high dose chemotherapy peripheral blood stem cell support patient recurrent refractory Hodgkin 's disease . II . Determine maximum tolerate dose etoposide combine carboplatin cyclophosphamide patient . OUTLINE : This dose escalation study etoposide . Patients undergo total nodal radiotherapy twice day day -35 -31 , -28 -24 , radiotherapy boost day day -21 -17 . Patients receive etoposide IV continuously carboplatin IV continuously day -6 -4 cyclophosphamide IV 2 hour day -3 -2 . Autologous peripheral blood stem cell infuse day 0 . Patients receive prior extensive radiation ( least 2000 cGy site ) receive chemotherapy peripheral blood stem cell infusion . Cohorts 4-8 patient receive escalate dos etoposide maximum tolerate dose ( MTD ) determine . The MTD define dose 1 4 2 8 patient experience dose limit toxicity . Patients follow every 1-3 month 2 year , every 3 month death . PROJECTED ACCRUAL : At least 4 patient accrue study .</detailed_description>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove Hodgkin 's disease Refractory standard therapy OR Relapsed follow initial complete remission Measurable evaluable disease Hepatic involvement must histologically prove consider sole area measurable disease If refer follow successful induction therapy , measurable evaluable disease require No CNS disease PATIENT CHARACTERISTICS : Age : Physiologic 65 Performance status : ECOG 02 Life expectancy : At least 2 month Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 50 mL/min Cardiovascular : No active heart disease No congestive heart failure No myocardial infarction past 3 month No significant arrhythmia require medication Ejection fraction normal Pulmonary : No significant nonneoplastic pulmonary disease No chronic obstructive pulmonary disease Diffusing capacity least 50 % predict OR FEV1 and/or FVC least 75 % predict ( unless due Hodgkin 's disease ) Other : Not pregnant Negative pregnancy test No active serious medical condition would preclude chemotherapy HIV negative No clinical evidence AIDS PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
</DOC>